<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hurley E</submitter><funding>Irish Research Council</funding><pagination>1163-1171</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11399282</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>46(5)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy (STOPPFrail) criteria aim to reduce inappropriate/unnecessary medications in frail older adults, which should minimise adverse drug events and additional healthcare expenditure. Little is known about the economic outcomes of applying these criteria as an intervention.&lt;h4>Aim&lt;/h4>To evaluate cost avoidance of pharmacist-led application of STOPPFrail to frail older nursing home residents with limited life expectancy.&lt;h4>Method&lt;/h4>Pharmacist-identified STOPPFrail-defined potentially inappropriate medications that were deprescribed by patients' general practitioners were assigned a rating by a multidisciplinary panel, i.e. the probability of an adverse drug event occurring if the </pubmed_abstract><journal>International journal of clinical pharmacy</journal><pubmed_title>Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes.</pubmed_title><pmcid>PMC11399282</pmcid><funding_grant_id>GOIPG/2020/1070</funding_grant_id><pubmed_authors>Dalton K</pubmed_authors><pubmed_authors>Foley T</pubmed_authors><pubmed_authors>Hurley E</pubmed_authors><pubmed_authors>Walsh E</pubmed_authors><pubmed_authors>Woods N</pubmed_authors><pubmed_authors>Byrne S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes.</name><description>&lt;h4>Background&lt;/h4>The Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy (STOPPFrail) criteria aim to reduce inappropriate/unnecessary medications in frail older adults, which should minimise adverse drug events and additional healthcare expenditure. Little is known about the economic outcomes of applying these criteria as an intervention.&lt;h4>Aim&lt;/h4>To evaluate cost avoidance of pharmacist-led application of STOPPFrail to frail older nursing home residents with limited life expectancy.&lt;h4>Method&lt;/h4>Pharmacist-identified STOPPFrail-defined potentially inappropriate medications that were deprescribed by patients' general practitioners were assigned a rating by a multidisciplinary panel, i.e. the probability of an adverse drug event occurring if the </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2026-06-02T11:50:14.026Z</modification><creation>2025-04-04T02:49:20.2Z</creation></dates><accession>S-EPMC11399282</accession><cross_references><pubmed>38967733</pubmed><doi>10.1007/s11096-024-01749-3</doi></cross_references></HashMap>